Bivalirudin in pediatric extracorporeal membrane oxygenation
Research article published in Current opinion in pediatrics (2022)
Abstract
PURPOSE OF REVIEW: This review summarizes the current literature surrounding the use of bivalirudin as an alternative anticoagulant for pediatric extracorporeal membrane oxygenation (ECMO) patients. RECENT FINDINGS: Recent single center studies describe that bivalirudin may be associated with decreased blood product transfusion, decreased cost and similar clinical outcomes for pediatric ECMO patients who have failed unfractionated heparin (UFH) anticoagulation. aPTT is the most common test to monitor bivalirudin but has several limitations. Other tests including dilute thrombin time (dTT) and viscoelastic assays are promising but more study is needed. Current evidence suggests that bivalirudin is a well tolerated and effective alternative anticoagulant for pediatric ECMO patients who have failed UFH anticoagulation but prospective studies are needed to confirm these results. SUMMARY: Bivalirudin is a promising alternative anticoagulant for pediatric ECMO patients who have failed UFH. Large prospective, multicenter studies are needed to confirm safety and efficacy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Bivalirudin in pediatric extracorporeal membrane oxygenation.
Por qué esto importa para la hirudoterapia
This review summarizes current literature on bivalirudin as an alternative anticoagulant for pediatric ECMO patients, particularly those who have failed unfractionated heparin (UFH). The review describes single-center studies suggesting bivalirudin may be associated with decreased blood product transfusion, decreased cost, and similar clinical outcomes, and discusses monitoring approaches including aPTT, dilute thrombin time, and viscoelastic assays. The abstract does not mention hirudin, leeches, or any leech-derived product, so no defensible connection to ASH's hirudotherapy domain can be drawn from this source. The authors conclude that large prospective multicenter studies are needed to confirm safety and efficacy.
Citación
Bivalirudin in pediatric extracorporeal membrane oxygenation
Ryerson LM et al. · Current opinion in pediatrics, 2022
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026